{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T18:28:34Z","timestamp":1649010514105},"reference-count":45,"publisher":"American Society of Consultant Pharmacists","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2005,11,1]]},"DOI":"10.4140\/tcp.n.2005.965","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:06:58Z","timestamp":1294884418000},"page":"965-975","source":"Crossref","is-referenced-by-count":0,"title":["An Update on Chronic Obstructive Pulmonary Disease"],"prefix":"10.4140","volume":"20","author":[{"given":"Roy A.","family":"Pleasants","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Haden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"1","unstructured":"Pauwels R, Anthonisen N, Bailey WC et al. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD): 2005; www.goldcopd.org. <a target=\"_blank\" href='http:\/\/www.goldcopd.org'>www.goldcopd.org<\/a>"},{"key":"2","article-title":"Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care","volume":"59","year":"2004","journal-title":"Thorax"},{"key":"3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"B Celli","year":"2004","journal-title":"Eur Respir J"},{"key":"4","article-title":"Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease: 2003","volume":"10","author":"D O'Donnell","year":"2003","journal-title":"Canadian Resp J"},{"key":"5","first-page":"762","article-title":"Chronic bronchitis, asthma, and pulmonary emphysema: a statement by the Committee on Diagnostic Standards in Nontuberculosis Respiratory Diseases","volume":"85","year":"1962","journal-title":"Am Rev Res Diseases"},{"key":"6","volume-title":"Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994","year":"1996"},{"key":"7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1378\/chest.117.4.1146","article-title":"Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education program","volume":"117","author":"G Ferguson","year":"2000","journal-title":"Chest"},{"key":"8","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1056\/NEJMra030415","article-title":"Management of chronic obstructive pulmonary disease","volume":"350","author":"E Sutherland","year":"2004","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1378\/chest.105.5.1411","article-title":"In chronic obstructive pulmonary disease, a combination of albuterol and ipratropium is more effective than either agent alone; an 85-day multicenter trial","volume":"105","year":"1994","journal-title":"Chest"},{"key":"10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1378\/chest.125.1.249","article-title":"The role of long-acting bronchodilators in the management of stable COPD","volume":"125","author":"D Tashkin","year":"2004","journal-title":"Chest"},{"key":"11","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1378\/chest.124.5.1743","article-title":"Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes","volume":"124","author":"B Celli","year":"2003","journal-title":"Chest"},{"key":"12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A six-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"J Donohue","year":"2002","journal-title":"Chest"},{"key":"13","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rmed.2004.10.004","article-title":"Bronchodilator response to formoterol after regular tiotropium or to tiotropium after regular formoterol","volume":"99","author":"M Cazzola","year":"2005","journal-title":"Resp Med"},{"key":"14","volume-title":"Boehinger Ingelheim and Pfizer, Sept","author":"Package Spiriva","year":"2004"},{"key":"15","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1056\/NEJM200012283432601","article-title":"Effect of triamcinolone on the decline on pulmonary function in chronic obstructive pulmonary disease","volume":"343","year":"2000","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomized, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial","volume":"320","author":"P Burge","year":"2000","journal-title":"BMJ"},{"key":"17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9343(02)01143-9","article-title":"The effects of inhaled corticosteroids in chronic obstructive pulmonary disease; a systematic review of randomized, placebo-controlled trials","volume":"113","author":"A Alsaeedi","year":"2002","journal-title":"Am J Med"},{"key":"18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(03)12459-2","article-title":"Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled clinical trial","volume":"361","author":"P Calverly","year":"2003","journal-title":"Lancet"},{"key":"19","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1378\/chest.124.3.834","article-title":"The efficacy and safety of fluticasone propionate (250 mcg)\/salmeterol (50 mcg) combined in the Diskus inhaler for the treatment of COPD","volume":"124","author":"N Hannania","year":"2003","journal-title":"Chest"},{"key":"20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.2112055","article-title":"Effectiveness of fluticasone propionate and salmeterol combination delivered via the discus device in the treatment of chronic obstructive pulmonary disease","volume":"166","author":"D Mahler","year":"2002","journal-title":"Am J Resp Crit Care Med"},{"key":"21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1164\/ajrccm.164.4.2009033","article-title":"Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease","volume":"164","author":"D Sin","year":"2001","journal-title":"Am J Resp Crit Care Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1164\/rccm.200206-606OC","article-title":"Inhaled corticosteroids and hip fracture. A population based case-control study","volume":"166","author":"R Hubbard","year":"2002","journal-title":"Am J Resp Crit Care Med"},{"key":"23","volume-title":"Mucolytic agents for chronic bron chitis or chronic obstructive pulmonary disease","year":"2004"},{"key":"24","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1001\/jama.283.24.3244","article-title":"A clinical practice guideline for treating tobacco use and dependence A U.S. Public Health Service Report","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-93-3-391","article-title":"Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial","volume":"93","year":"1980","journal-title":"Ann Intern Med"},{"key":"26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(00)04237-9","article-title":"Effects of a large scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study","volume":"357","author":"B Christenson","year":"2001","journal-title":"Lancet"},{"key":"27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1056\/NEJMoa025028","article-title":"Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly","volume":"348","author":"K Nichol","year":"2003","journal-title":"N Engl J Med"},{"key":"28","unstructured":"Cochrane Database of Systematic Reviews 2000;CD00273 Poole PJ et al. Influenza vaccine for patients with chronic obstructive pulmonary diseases."},{"key":"29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1098-3597(03)90006-8","article-title":"Treatment of acute exacerbations of COPD","volume":"5","author":"A Blanchard","year":"2003","journal-title":"Clinical Cornerstone"},{"key":"30","article-title":"Towards a consensus definition of a COPD exacerbations","volume":"117","author":"R Rodriguez-Rosin","year":"2000","journal-title":"Chest"},{"key":"31","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/jama.274.23.1852","article-title":"Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease","volume":"274","author":"M Seneff","year":"1995","journal-title":"JAMA"},{"key":"32","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1592\/phco.21.11.929.34523","article-title":"Konsem SL. Management of acute exacerbations of chronic obstructive pulmonary disease","volume":"21","author":"J Adkison","year":"2001","journal-title":"Pharmacotherapy"},{"key":"33","doi-asserted-by":"crossref","first-page":"600","DOI":"10.7326\/0003-4819-134-7-200104030-00016","article-title":"Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence","volume":"134","author":"P Bach","year":"2001","journal-title":"Ann Intern Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1378\/chest.117.5.1345","article-title":"Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD","volume":"117","author":"S Adams","year":"2000","journal-title":"Chest"},{"key":"35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ageing\/afh062","article-title":"Inhaler technique in older people in the community","volume":"33","author":"S Ho","year":"2004","journal-title":"Age Aging"},{"key":"36","article-title":"Inter-individual variability of peak inhalation rates through different inhalers in asthmatic children and adults with COPD","author":"W Tarsin","year":"2001","journal-title":"Eur Resp J"},{"key":"37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/rmed.2003.1351","article-title":"Is inhalation rate important for a dry powder inhaler; using the In-Check dial to check these rates","volume":"97","author":"R Chrystyn","year":"2003","journal-title":"Resp Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1183\/09031936.97.10092105","article-title":"Flow dependent effect of formoterol dry-powder inhaled from the Aerolizer","volume":"10","author":"K Neilsen","year":"1997","journal-title":"Eur Resp J"},{"key":"39","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/08942680152744703","article-title":"In vitro aerosol performance and dose uniformity between the Foradil Aerolizer and the Oxis Turbuhaler","volume":"14","author":"N Chew","year":"2001","journal-title":"J Aerosol Med"},{"key":"40","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/rmed.2001.1044","article-title":"Ex-vivo product performance of Diskus and Turbuhaler using inhalational profiles from patients with severe chronic obstructive pulmonary disease","volume":"95","author":"P Burnell","year":"2001","journal-title":"Resp Med"},{"key":"41","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.rmed.2004.08.002","article-title":"Comparison of effects of nebulized and inhaled salbutamol on breathlessness in severe COPD","volume":"99","author":"P Poole","year":"2005","journal-title":"Resp Med"},{"key":"42","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.rmed.2004.04.010","article-title":"The course of inhalational profiles during an exacerbation of obstructive lung disease","volume":"98","author":"M Broerders","year":"2004","journal-title":"Resp Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/089426801316970268","article-title":"Effective delivery of particles with the Handihaler inhalational system over a range of COPD severity","volume":"14","author":"F Chodosh","year":"2001","journal-title":"J Aerosol Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/qhc.11.4.376","article-title":"Inhaler devices for the treatment of asthma and chronic obstructive lung disease","volume":"11","author":"J Wright","year":"2002","journal-title":"Qual Safe Health Care"},{"key":"45","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1365-2125.1990.tb05446.x","article-title":"A comparison of the effects of zolpidem and placebo on respiration and oxygen saturation during sleep in the healthy elderly","volume":"30","author":"S Rhodes","year":"1990","journal-title":"Br J Clin Pharmacol"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:04:08Z","timestamp":1559937848000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2005\/00000020\/00000011\/art00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11,1]]}},"alternative-id":["E16V11H11653W36T"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2005.965","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}